Related Experiment Video
Updated: Dec 11, 2025
07:29
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
20.0K
When, why and how tumour clonal diversity predicts survival
Robert Noble1,2,3,4, John T Burley5,6, Cécile Le Sueur1
1Department of Biosystems Science and Engineering ETH Zurich Basel Switzerland.
Evolutionary Applications
|August 22, 2020
Summary
Intratumour heterogeneity can predict tumour growth and survival. Understanding tumour evolution reveals how clonal diversity acts as a prognostic biomarker in oncology.
Area of Science:
- Computational biology
- Cancer research
- Evolutionary medicine
Background:
- Intratumour heterogeneity is a key factor in cancer progression.
- Its role as a prognostic biomarker is under investigation.
- The evolutionary mechanisms linking heterogeneity to clinical outcomes are not fully understood.
Purpose of the Study:
- To investigate the relationship between intratumour heterogeneity and tumour growth rate.
- To determine how clonal diversity can predict progression-free survival.
- To explain empirical findings in cancer using evolutionary theory.
Main Methods:
- Utilizing a spatial computational model of tumour evolution.
- Analyzing conditions influencing the correlation between clonal diversity and tumour growth.
- Examining tumour cohorts with diverse evolutionary parameters.
Main Results:
- Identified conditions for positive and negative correlations between clonal diversity and growth rate.
- Clonal diversity reliably predicts tumour growth rate and progression-free survival.
- Provided evolutionary explanations for observed cancer progression patterns.
Conclusions:
- Clonal diversity is a valuable prognostic biomarker in cancer.
- Understanding tumour evolutionary dynamics is crucial for predictive oncology.
- The study offers insights into cancer progression and informs biomarker development.
Related Concept Videos
01:21Cancer Survival Analysis
564
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
564
02:07Tumor Progression
7.1K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.1K
02:40Cancer Stem Cells and Tumor Maintenance
5.7K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.7K
01:22T Cell Activation and Clonal Selection
14.3K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
14.3K
02:18Cancer
53.1K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
53.1K
01:27Tumor Immunotherapy
1.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.5K